NCT02303041View on ClinicalTrials.gov

Pilot Study of Sonidegib and Buparlisib in Treating Patients With Advanced or Metastatic Basal Cell Carcinoma

PHASE2TerminatedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

April 30, 2017

Study Completion Date

June 30, 2017

Conditions
Carcinoma, Basal CellRecurrent Skin CancerSkin NeoplasmsBasal Cell Nevus Syndrome
Interventions
DRUG

Buparlisib

Administered orally at starting dose of 80 mg/day

DRUG

Sonidegib

Administered orally at starting dose of 200 mg/day

Trial Locations (1)

94305

Stanford University School of Medicine, Stanford

Sponsors

Collaborators (1)

Novartis Pharmaceuticals
All Listed Sponsors
collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

Anne Chang

OTHER